Finding Links Between Hot flASHes and CardioVascular Disease (NCT07077395) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Finding Links Between Hot flASHes and CardioVascular Disease
United States80 participantsStarted 2026-04
Plain-language summary
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Who can participate
Age range40 Years – 65 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 40-65 years
* Peri- and post-menopausal women (STRAW -1 to +1)
* Moderate or high vasmotor symptom burden
* Cardiometabolic disease (as evidenced by ≥ 2 of the following):
* Obesity (body mass index ≥ 30 kg/m2)
* Elevated waist circumference (≥ 88 cm)
* Elevated triglycerides (≥ 150 mg/dL or drug treatment)
* Reduced HDL-cholesterol (\<50 mg/dL or drug treatment)
* Elevated blood pressure (≥ 130 mmHg systolic blood pressure or ≥ 85 mmHg diastolic blood pressure, or drug treatment)
* Elevated fasting glucose (≥ 100 mg/dL or drug treatment)
Exclusion Criteria:
* Inability to provide informed consent or comply with study protocol
* Major comorbidities: cancer, end-stage renal (eGFR \<45 mL/min/1.73 m2), liver or lung disease
* Concomitant use of strong or moderate cytochrome P450 3A4 inhibitors
* Elevated liver function tests (ALT, AST, and/or total bilirubin ≥2x ULN)
* Undiagnosed uterine bleeding over past 6 months